– New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – Deal worth up to $415m including upfront and downstream, plus royalties on top – ATLX-1282 is the first programme out of Alchemab’s entirely novel platform which generates and analyses millions of antibody sequences […]
Copenhagen, Denmark, 30 May 2024 – Vesper Bio ApS (“Vesper” or “the Company”), a clinical stage biotech and world leader in sortilin receptor biology, today announces completion of the single ascending dose stage of its first-in-human trial of VES001 in healthy volunteers. VES001 is the first oral, brain penetrant, small molecule sortilin inhibitor designed as […]
Lausanne, SWITZERLAND and San Francisco, CA, USA, 4 May 2022 – Asceneuron SA, a clinical stage company dedicated to targeting the root causes of neurodegenerative diseases, today announces that it has been awarded a second grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the study of its clinical stage O-GlcNAcase (OGA) […]
